Nateglinide - current and future role in the treatment of patients with type 2 diabetes mellitus
Tóm tắt
Từ khóa
Tài liệu tham khảo
King, 1998, Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections, Diabetes Care, 21, 1414, 10.2337/diacare.21.9.1414
Weyer, 1999, The natural history of insulin secretory dysfunction and resistance in the pathogenesis of type 2 diabetes mellitus, J Clin Invest, 104, 787, 10.1172/JCI7231
Lowe, 1997, Diabetes, asymptomatic hyperglycaemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study, Diabetes Care, 20, 163, 10.2337/diacare.20.2.163
Stratton, 2000, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study, BMJ, 321, 405, 10.1136/bmj.321.7258.405
Khaw, 2001, Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk), BMJ, 322, 15, 10.1136/bmj.322.7277.15
Lee, 2000, Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies, Diabetes Care, 23, 692, 10.2337/diacare.23.7.962
Balkau, 1998, High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men, Diabetes Care, 21, 360, 10.2337/diacare.21.3.360
DECODE Study Group, on behalf of the European Diabetes Epidemiology Group, 2001, Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria, Arch Intern Med, 161, 397, 10.1001/archinte.161.3.397
Nakagami, 2004, Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin, Diabetologia, 47, 385, 10.1007/s00125-004-1334-6
Califf R Holman R on behalf of the NAVIGATOR Trial Group.
Ceriello, 2005, Postprandial hyperglycemia and diabetes complications: is it time to treat?, Diabetes, 54, 1, 10.2337/diabetes.54.1.1
Davies, 2005, Post-prandial hyperglycemia and prevention of cardiovascular disease, Diabet Med, 22, 1, 10.1111/j.1464-5491.2005.1531d.x
Fonseca, 2003, Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus, Curr Med Res Opin, 19, 635, 10.1185/030079903125002351
Home, 2005, Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes, Curr Med Res Opin, 21, 989, 10.1185/030079905X49662
American Diabetes Association., 2005, Standards of medical care, Diabetes Care, 28, S4, 10.2337/diacare.28.suppl_1.S4
European Diabetes Policy Group., 1999, A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999, Diabet Med, 16, 716
Dinneen, 1995, Mechanism of postprandial hyperglycaemia in diabetes mellitus, Eur J Gastroenterol Hepatol, 7, 724
Gavin, 2001, Pathophysiologic mechanisms of postprandial hyperglycemia, Am J Cardiol, 88, 4H, 10.1016/S0002-9149(01)01830-6
Del Prato, 2003, Loss of early insulin secretion leads to postprandial hyperglycaemia, Diabetologia, 46, M2, 10.1007/s00125-002-0930-6
Bastyr, 2000, Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c, Diabetes Care, 23, 1236, 10.2337/diacare.23.9.1236
Quast, 2004, The impact of ATP-sensitive K channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium, Diabetes, 53, S156, 10.2337/diabetes.53.suppl_3.S156
Hu, 2002, Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action, Eur J Pharmacol, 442, 163, 10.1016/S0014-2999(02)01499-1
Hu, 2000, Pancreatic β-cell KATP channel activity and membrane binding studies with nateglinide: a comparison with sulfonylureas and repaglinide, J Pharmacol Exp Ther, 293, 444
Laghmich, 1999, Long-term effect of glibenclamide and nateglinide upon pancreatic islet cell function in normal and diabetic rats, Pharmacol Res, 40, 475, 10.1006/phrs.1999.0551
Maedler, 2005, Sulfonylurea induced beta-cell apoptosis in cultured human islets, J Clin Endocrinol Metab, 90, 501, 10.1210/jc.2004-0699
Chachin, 2003, Nateglinide, a d-phenylalanine derivative lacking either a sulfonylurea or a benzamido moiety, specifically inhibits pancreatic β-cell-type KATP channels, J Pharmacol Exp Ther, 304, 1025, 10.1124/jpet.102.044917
McLeod, 2004, Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent, Clin Pharmacokinet, 43, 97, 10.2165/00003088-200443020-00003
Weaver, 2001, Pharmacokinetics and metabolism of nateglinide in humans, Drug Metab Dispos, 29, 415
Luzio, 2001, Effects of timing on administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycaemic agent nateglinide in healthy subjects, J Clin Endocrinol Metab, 86, 4874, 10.1210/jcem.86.10.7911
Keilson, 2000, Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus, J Clin Endocrinol Metab, 85, 1081, 10.1210/jcem.85.3.6446
Uchino, 2000, Impairment of early insulin response after glucose load, rather than insulin resistance, is responsible for postprandial hyperglycemia seen in obese type 2 diabetes: assessment using nateglinide, a new insulin secretagogue, Endocr J, 47, 639, 10.1507/endocrj.47.639
Whitelaw, 2000, Effects of the new oral hypoglycaemic agent nateglinide on insulin secretion in Type 2 diabetes mellitus, Diabet Med, 17, 225, 10.1046/j.1464-5491.2000.00256.x
Carroll, 2002, Control of postprandial hyperglycemia. Optimal use of short-acting insulin secretagogues, Diabetes Care, 25, 2147, 10.2337/diacare.25.12.2147
Carroll, 2003, Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes, J Clin Endocrinol Metab, 88, 5248, 10.1210/jc.2003-030649
Barnett, 2004, A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes, Diabetes Obes Metab, 6, 104, 10.1111/j.1462-8902.2004.00321.x
Vakkilainen, 2002, Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes, Diabetes Metab Res Rev, 18, 484, 10.1002/dmrr.324
Abrahamian, 2004, Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring, Diabetes Technol Ther, 6, 31, 10.1089/152091504322783387
Hirose, 2002, The effects of nateglinide following oral glucose load in impaired glucose tolerance subjects: rapid insulin secretion by nateglinide in IGT subjects, Endocr J, 49, 649, 10.1507/endocrj.49.649
Shiba, 2003, Improvement of insulin resistance by a new insulin secretagogue, nateglinide - analysis model based on the homeostasis model, Diabetes Res Clin Pract, 62, 87, 10.1016/S0168-8227(03)00169-4
Hollander, 2001, Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes, Diabetes Care, 24, 983, 10.2337/diacare.24.6.983
Abletshauser, 2005, Effect of nateglinide and glimepiride in reducing postprandial hyperglycaemia in patients with type 2 diabetes mellitus, Br J Diabetes Vasc Dis, 5, 93, 10.1177/14746514050050020701
Shimabukuro, 2004, A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients, Diabet Med, 21, 983, 10.1111/j.1464-5491.2004.01272.x
Esposito, 2004, Regression of carotid atherosclerosis by control of postprandial hyperglycaemia in type 2 diabetes mellitus, Circulation, 110, 214, 10.1161/01.CIR.0000134501.57864.66
Mero, 1998, Postprandial lipid metabolism in diabetes, Atherosclerosis, 141, S53, 10.1016/S0021-9150(98)00218-4
Ceriello, 2002, Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation. Effects of short- and long-term simvastatin treatment, Circulation, 106, 1211, 10.1161/01.CIR.0000027569.76671.A8
Ceriello, 2004, Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment, Diabetes, 53, 701, 10.2337/diabetes.53.3.701
Teno, 2000, Association of postprandial hypertriglyceridemia and carotid intima-media thickness in patients with type 2 diabetes, Diabetes Care, 23, 1401, 10.2337/diacare.23.9.1401
Mine, 2002, Nateglinide suppresses postprandial hypertriglyceridemia in Zucker Fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide, Biol Pharm Bull, 25, 1412, 10.1248/bpb.25.1412
Kitahara Y Miura K Kajioka T Mine T.
Mori, 2004, Effects of nateglinide on the elevation of postprandial remnant-like particle triglyceride levels in Japanese patients with type 2 diabetes assessment by meal tolerance test, Endocrine, 25, 203, 10.1385/ENDO:25:3:203
Dimitriadis, 2004, Restoration of early insulin secretion after a meal in type 2 diabetes: effects on lipid and glucose metabolism, Eur J Clin Invest, 34, 490, 10.1111/j.1365-2362.2004.01377.x
Hanefeld, 2000, Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia, Diabetes Care, 23, 202, 10.2337/diacare.23.2.202
Saloranta, 2002, Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia, J Clin Endocrinol Metab, 87, 4171, 10.1210/jc.2002-020068
Rosenstock, 2002, Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes, Diabetes Care, 25, 1529, 10.2337/diacare.25.9.1529
Schwartz SL Purkayastha DD Marcellari A Baron MA. 1c
Horton, 2004, Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naive patients with type 2 diabetes, Curr Med Res Opin, 20, 883, 10.1185/030079903125003881
Notoya, 2005, Nateglinide - its positioning in the intervention for type 2 diabetes, Prog Med, 25, 767
Taki, 2003, Post-marketing surveillance study of nateglinide in Japan, Prog Med, 23, 3369
Turner, 1999, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). The UK Prospective Diabetes Study (UKPDS) Group, JAMA, 281, 2005, 10.1001/jama.281.21.2005
Cook, 2005, Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 disbetes, Diabetes Care, 28, 995, 10.2337/diacare.28.5.995
UK Prospective Diabetes Study (UKPDS) Group., 1998, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet, 352, 854, 10.1016/S0140-6736(98)07037-8
Marre, 2002, Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients, Diabetes Obes Metab, 4, 177, 10.1046/j.1463-1326.2002.00196.x
Schatz, 2003, Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions, Exp Clin Endocrinol Diabetes, 111, 262, 10.1055/s-2003-41752
Salas, 2002, Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus, Clin Ther, 24, 1690, 10.1016/S0149-2918(02)80072-8
Fonseca, 2003, Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control, Diabetes Care, 26, 1685, 10.2337/diacare.26.6.1685
Kosaka, 1997, Phase-III study of a novel hypoglycaemic agent, AY1466, on NIDDM patients in Japan: α-glucosidase inhibitor, voglibose-controlled multicenter double blind study, Clin Pharmacol Ther, 7, 699
Weaver, 2004, Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84, Diabetes Obes Metab, 6, 344, 10.1111/j.1462-8902.2004.00353.x
Del Prato, 2003, Treatment of patients over 64 years of age with type 2 diabetes, Diabetes Care, 26, 2075, 10.2337/diacare.26.7.2075
Suzuki, 2004, Long-term efficacy of nateglinide after short-term insulin treatment to remove glucose toxicity in poorly controlled type 2 diabetes, J Japan Diab Soc, 47, 265
Takahashi K Yoshida A Fujita M Kusumoto T. 25:
Kanda, 2004, Clinical parameters for predicting possibility of insulin therapy withdrawal in patients with type 2 diabetes mellitus, J Japan Diab Soc, 47, 271
Terui, 2000, Nateglinide efficacy in two subjects with glucocorticoid-induced hyperglycemia, Prog Med, 20, 1645
Anderson, 2005, Pharmacologic prevention or delay of type 2 diabetes mellitus, Ann Pharmacother, 39, 102, 10.1345/aph.1E081
Irons, 2004, Delaying the onset of type 2 diabetes mellitus in patients with prediabetes, Pharmacotherapy, 24, 362, 10.1592/phco.24.4.362.33170
Saloranta, 2002, Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population, Diabetes Care, 25, 2141, 10.2337/diacare.25.12.2141
Mari, 2005, β-cell function in mild type 2 diabetic patients. Effects of 6-month glucose lowering with nateglinide, Diabetes Care, 28, 1132, 10.2337/diacare.28.5.1132
Diabetes Control and Complications Trial Research Group., 1997, Hypoglycemia in the Diabetes Control and Complications Trial, Diabetes, 46, 271, 10.2337/diab.46.2.271
Belcher, Safety and Tolerability of pioglitazone, metformin, and gliclazide in the Treatment of Type 2 Diabetes, Diabetes Res Clin Pract
Riddle, 2000, Combining sulfonylureas and other oral agents, Am J Med, 108, 15S, 10.1016/S0002-9343(00)00338-7
Fonseca, 2004, Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus, Metabolism, 53, 1331, 10.1016/j.metabol.2004.05.009
Diamant, 2003, Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence, Drugs, 63, 1373, 10.2165/00003495-200363130-00004
Novo Nordisk Pharmaceuticals., 1998, Prandin (repaglinide) tablets (0.5, 1 and 2 mg) package insert
Taki, 2004, Post-marketing study of nateglinide in Japan: Treatment of medication-naïve patients with mild type II diabetes, Prog Med, 24, 1104
Iso, 2004, Study of Nateglinide in Japan: long-term treatment of type 2 diabetes, Prog Med, 24, 1104
Anderson, 2002, A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers, Int J Clin Pharmacol Ther, 40, 457, 10.5414/CPP40457
Anderson, 2002, No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers, J Clin Pharmacol, 42, 1358, 10.1177/0091270002238772
Niemi, 2003, Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide, Diabetologia, 46, 347, 10.1007/s00125-003-1034-7
Devineni, 2003, Pharmacokinetics of nateglinide in renally impaired diabetic patients, J Clin Pharmacol, 43, 163, 10.1177/0091270002239825
Inoue, 2003, Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure, Clin Nephrol, 60, 90, 10.5414/CNP60090
Nagai, 2003, Hypoglycaemia due to nateglinide administration in diabetic patients with chronic renal failure, Diabet Res Clin Pract, 59, 191, 10.1016/S0168-8227(02)00242-5
Novartis Pharmaceuticals., 2002, Starlix® (nateglinide tablets): prescribing information.